Company Overview of Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein primarily in Europe, the United States, and Asia. KLH is an immune-stimulating protein used for generation of antibody and cell-mediated immune responses against disease indications, such as cancer, immune disorders, Alzheimer’s, and inflammatory diseases, as well as used for therapeutic vaccine conjugation in immunotherapies. The company also offers in vitro diagnostic kits for preclinical use. It provides its products under the Stellar KLH brand name. The company serves multinational biotechnology and pha...
332 East Scott Street
Port Hueneme, CA 93041
Key Executives for Stellar Biotechnologies, Inc.
Total Annual Compensation: $402.3K
Chief Financial Officer and Corporate Secretary
Total Annual Compensation: $175.0K
Chief Operations Officer
Total Annual Compensation: $155.8K
Compensation as of Fiscal Year 2014.
Stellar Biotechnologies, Inc. Key Developments
Stellar Biotechnologies, Inc. Announces Consolidated Earnings Results for the Year Ended August 31, 2014
Nov 13 14
Stellar Biotechnologies, Inc. announced consolidated earnings results for the year ended August 31, 2014. For the year, the company reported total revenues of $372,132 compared to $545,469 for the same period a year ago. Net loss was $8,439,523 against $14,495,779 a year ago. The lower loss in the current year was primarily affected by noncash changes in fair value of warrant liability. Basic and diluted loss per common share was $0.11 against $0.28 a year ago. Net cash used in operating activities was $4,266,707 against $2,795,823 a year ago.
Stellar Biotechnologies and Araclon Biotech Sign Exclusive KLH Supply Agreement for Clinical Trials in Alzheimer's Active Immunotherapies
Nov 11 14
Stellar Biotechnologies, Inc. and Araclon Biotech SL announced that the companies have executed a definitive exclusive supply agreement to meet Araclon's Phase (II and III) clinical trial requirements for Keyhole Limpet Hemocyanin (KLH) used in Araclon's active immunotherapies against Alzheimer's disease. The purpose of the agreement is to ensure a stable supply to Araclon of Stellar KLH(TM) for the ongoing clinical development of Araclon's Alzheimer's drugs, including the development of manufacturing processes, production capacity and regulatory support. Under the agreement, Araclon will manage and fund all product development and regulatory submissions for its products. Stellar will supply GMP-grade Stellar KLH(TM) protein and will provide technical and regulatory support to Araclon. The agreement requires Stellar to deliver the first batch of Stellar KLH(TM) to Araclon by December 31, 2014. Araclon and Stellar have entered into a mutually exclusive contract for the supply of KLH for Araclon's beta amyloid peptide in the Alzheimer's space throughout the term of the agreement for use in Araclon's upcoming clinical trials with an active immunotherapy against Alzheimer's disease at agreed prices. Stellar and Araclon have agreed upon first negotiation rights for the exclusive supply of Stellar KLH(TM) in connection with the potential future commercialization by Araclon of its beta amyloid-targeting immunotherapy products. The agreement has an initial five-year term, which may be renewed by Araclon, if necessary, for additional one-year periods.
Stellar Biotechnologies, Inc. Presents at LD Micro Conference, Dec-02-2014 01:00 PM
Nov 8 14
Stellar Biotechnologies, Inc. Presents at LD Micro Conference, Dec-02-2014 01:00 PM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Boulevard, Los Angeles, California, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|